Surmodics Agrees to $627M Acquisition by GTCR

Surmodics, Inc., a leading medical device and in vitro diagnostic technologies provider, has been definitively acquired by GTCR, a prominent private equity firm with a longstanding history of investment in the healthcare sector. The acquisition agreement, unanimously approved by Surmodics’ Board of Directors, entails the purchase of all outstanding shares of Surmodics by GTCR affiliates for a cash consideration of $43.00 per share. This translates to an approximate total equity valuation of $627 million for Surmodics.

The per-share acquisition price represents a significant premium of 41.1% over Surmodics’ 30-day volume-weighted average closing stock price leading up to May 28, 2024. This suggests that GTCR values Surmodics’ potential for future growth and profitability considerably higher than its current market valuation. The transaction is anticipated to be finalized following the fulfillment of customary closing conditions and shareholder approval.

Surmodics’ Board of Directors has endorsed the agreement and urged stockholders to vote in favor of the acquisition. The Board believes the transaction offers stockholders a compelling financial return and positions Surmodics for continued success under GTCR’s ownership. GTCR’s healthcare and healthcare technology expertise is expected to propel Surmodics’ future endeavors.

The acquisition will likely have a consequential impact on Surmodics’ operations and strategic direction. GTCR’s involvement could lead to increased investment in research and development, expanded market reach, and the exploration of new opportunities within the medical technology landscape. The details regarding how GTCR plans to integrate Surmodics into its portfolio remain to be disclosed.

This acquisition underscores the ongoing consolidation within the medical device and diagnostics industry. Strategic acquisitions like this become increasingly commonplace as companies seek to expand their product offerings and broaden their market footprint. The combined entity of Surmodics and GTCR’s healthcare portfolio has the potential to become a significant player in the industry.